G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs RRx 001 (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- Acronyms G-FORCE-1
- Sponsors EpicentRx
- 02 Jul 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
- 02 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
- 02 Jul 2017 Status changed from not yet recruiting to recruiting.